The Zhitong Finance App learned that Yamato released a research report saying that the Phase III study of Kangfang Biotech (09926.HK) iwasi first-line treatment for PD-L1 expression positive NSCLC, as assessed by an independent data monitoring committee, showed that the study reached a critical secondary OS end point. The bank maintained Kangfang Biotech's “buy” rating. Yamato believes that this result further validates the OS clinical benefit of evosimab in first-line NSCLC treatment, successfully translating from strong progression-free survival (PFS) clinical benefits.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.